Iverson's Network Lab opens at the Morehouse School of Medicine in Atlanta, GA
Iverson recently opened a network lab at the Morehouse School of Medicine in Atlanta, GA. Iverson CEO, Dean Sproles released a statement saying, "Personal, gene-based information is the next wave of optimizing therapy and enhancing personal wellness for patients. This genetic testing laboratory at Morehouse School of Medicine will provide physicians and other healthcare providers in Georgia and around the nation with more specific gene-based information to optimize the care of their patients. For example, gene-based information from this lab will help physicians understand how a patient may respond to a specific drug and effectively introduce clinically relevant genetic testing into mainstream medicine."
Click here to read the full press release.
Morehouse School of Medicine
Iverson Bothell Lab accredited by CAP (College of American Pathologists)
On August 31st, two doctors from the Molecular Pathology Laboratory at Creighton University Medical School in Nebraska visited our headquarters in Bothell for our first College of American Pathologists (CAP) laboratory inspection. Although Iverson has been certified for several years under the federal CLIA inspection and licensure program, Iverson elected to have a CAP inspection as well. CAP’s mission is more than regulatory, it is also educational. CAP inspections aim to provide interaction between the inspectors, who are functioning lab directors or technicians, and those being inspected, in order to share ideas for laboratory improvement. We had a successful inspection and obtained ideas for improvement. As of October 12th, 2009 Iverson Genetic Diagnostics, Inc. is CAP certified. Congratulations to Iverson and the amazing lab team led by Dr. Laurance Ferreri in Bothell, WA.
Click here to learn about CAP.
Iverson attended The 30th Annual SWAHAP (the Southwest Association of Hispanic American Physicians) Medical Education Congress in El Paso, TX on Nov. 13-14.
Iverson recently attended a conference hosted by the Southwest Association of Hispanic American Physicians, in joint sponsorship with Sierra Providence Health Network. Over 200 physicians, over 100 nurses and other healthcare professionals throughout West Texas and New Mexico were in attendance.
Click here to learn more about the SWAHAP conference.
Iverson attended the 5th Annual Burrill Personalized Medicine Meeting at the Mission Bay Conference Center at UC San Francisco on Nov. 9-10
We recently attended the 5th Annual Burrill Personalized Medicine Meeting, a two-day event, which encompasses detailed discussions on the spectrum of personalized medicine – from prediction to prevention. The event provided attendees with a detailed 'window'into the emerging personalized medicine world. This year brought together researchers, drug developers, diagnostics manufacturers, clinicians, payors, investors, public policy experts, medical ethicists and patients for a fascinating and instructive set of conversations focusing on the impact that broader healthcare reform will have on personalized medicine.
Click here to visit the conference website.
Iverson's International Growth
Iverson is seeking international patent protection for our Broad-Based Gene Transcript Test in China, Canada, and the EU. Also, paperwork is in progress for regulatory approval permits to have specimens cross the border from Canada, Mexico, Puerto Rico and Barbados.
Iverson attended the 2009 Fall MedAxiom Conference in Monarch Beach, CA, Sept 23rd - 25th
Iverson is attended the 2009 Fall MedAxiom Conference in Monarch Beach, CA, Sept 23rd - 25th, 2009. MedAxiom is one of the most valuable resources a cardiology practice can have. They are a comprehensive subscription-based service provider and information resource exclusively for cardiology practices. Their network has grown to over 300 practices representing 5,400 physicians across the U.S. MedAxiom is a community of cardiology practice executives, administrative leaders, physicians and business office teams that strive to be more effective and efficient through sharing of operational practice data, best practice business strategies, positive and negative experiences as well as insights into the future of cardiology. MedAxiom's services are anchored by cardiology-specific comparative statistical analysis and benchmark reporting on financial, operational, and clinical functions within the practice. They collect well over 600 data points covering all facets of cardiology practice operations.
Click here to learn more.
Iverson attended the 2009 Fall Meeting for the Texas Medical Group Management Association
Iverson
attended the 2009 Fall Texas Medical Group Management Association in
Austin, TX on September 3rd and 4th.The Texas Medical Group Management
Association is a professional association of medical practice
administrators founded in 1973, representing over 400 practice
administrators in Texas. Texas MGMA has over 500 members representing
over 374 medical practices. Approximately 50% of members work in
practices that are 10+ physicians. Approximately 50% of members work in
practices with 10 physicians or less.
Click here to learn more.
Iverson Partners With Leading Hospitals to Address Warfarin Pharmacogenetic Testing
In a collaborative effort, Iverson Genetic Diagnostics, Inc. has partnered with leading decision makers in participating hospital networks to establish a steering committee to develop a protocol and create a clinical trial aimed at addressing CMS's proposal for Warfarin pharmacogenetic testing. Hospital networks nationwide will have the opportunity to participate, and collect data to identify the primary outcomes of warfarin sensitivity testing and personalized dose recommendations for individuals who are initiating warfarin therapy.
Estrogen Metabolism Panel Coming Soon!
Iverson is developing an Estrogen Metabolism Panel to evaluate how estrogen is processed in the body prior to prescribing hormone replacement therapy. The estimated product release date is scheduled for September 1st, 2009. Additionally, a comprehensive Women's Health Initiative Panel which will follow. The test will include specific genetic variants associated with women's health concerns, such as estrogen metabolism, Tamoxifen responsiveness, Thrombosis risk, and HPV risk. Release date is TBD.
Iverson's Lab Participating in Blood vs. Buccal Swab Study
Iverson's Laboratory has collected 60 samples to provide information on the efficacy of the non-invasive buccal swab collection technique. The samples will be run on the Osmetech Warfarin extended panel assay, and include a broad range of ages, ethnic backgrounds, and male and female participants.
Iverson National Coverage Update
Iverson has extended its list of credentialed national insurance providers and is in the process of becoming credentialed with all major hospital systems in the U.S.
|
